Stemline Therapeutics, Inc. Announces Presentations at the 2013 American Society of Clinical Oncology Annual Meeting
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK, May 30, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today announced that SL-401 clinical results in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), and preclinical results in multiple myeloma (MM), have been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 31-June 4 in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
NEW YORK, May 30, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today announced that SL-401 clinical results in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), and preclinical results in multiple myeloma (MM), have been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 31-June 4 in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.